Viral Vector Manufacturing: Current Landscape and Opportunities
Over the last few decades, various viral vector manufacturing have been developed, optimized and standardized for introduction of therapeutic DNA / gene of interest into a patient’s body / cells. Currently, the most popular viral vectors, on the basis of their use in active clinical trials, are those based on AAV, adenovirus, lentivirus and retrovirus. On the other hand, among non-viral gene delivery tools, plasmid DNA has emerged as the preferred option. Overall, eleven gene therapies have been approved so far.
In addition, over 430 gene therapy candidates are presently in different stages of clinical development, for which over 500 clinical studies are currently underway in various regions across the globe. The growing number of gene therapy candidates, coupled with their rapid progression through various phases of clinical development, is expected to continue to create an increasing demand for viral vector manufacturing.
Rising Optimism Amongst Stakeholders is Driven by Increasing Outsourcing Trend
Opinions expressed by industry stakeholders highlight the increasing outsourcing trend of viral vector manufacturing for the development of genetically modified therapies.
Over 160 Organizations are Involved in the Manufacturing of Viral / Plasmid DNA Vector
The landscape is well distributed across vector types; a number of facilities are operating at the lab / clinical scale with significant support from academic / non-industry players
CMOs are Acting as Key Enablers to Cater to the Growing Demand
Advances in genetically modified therapies have led to an increase in the demand of vectors; CMOs enable an accelerated transition towards commercial development. Viral vector and non viral vector manufacturing companies are Advanced BioScience Laboratories, AGC Biologics, Aldevron, Altruist Biotechnology, BioNTech Innovative Manufacturing Service (a subsidiary of BioNTech), BioReliance (a subsidiary of Merck KGaA), Biovian, Catalent Biologics, Celonic, Centre for Process Innovation
The Manufacturing Activity is Heavily Concentrated in the US and the EU
To cater to the growing global demand, companies have established presence across different regions; the US and EU have emerged as key hubs.
Overall Installed Manufacturing Capacity will Likely Witness Significant Growth
The installed vector manufacturing capacity is estimated to be over 50 thousand litres; in order to maintain a competitive advantage, stakeholders are looking to expand further
As Companies Actively Collaborate, Novel Vectors are Being Investigated
Increasing instances of partnerships showcase the rising interest in this domain; companies are actively collaborating to develop novel manufacturing technology platforms.
Driven by Adoption of Advanced Technologies
Our outlook is highly promising; overall, we expect the market to grow at an annualized rate of over 20% during the next decade.
We Expect the Market to Grow at an Accelerated Pace
In the short-term, clinical products are expected to dominate the market; commercial scale will gradually become mainstream in about five years
Overall, the Long Term Opportunity is Likely to be Well-Distributed
As expected, oncology will account for a significant share of the viral vector manufacturing market; the future opportunity is expected to be well-distributed amongst vector types in the long-term.
For more details, you can also download the SAMPLE REPORT on viral vector manufacturing by Roots Analysis.
Cell and Gene Therapy Technology Update: ReNeuron Presents Positive Data
T-Cell Immunotherapy: The Next Big Thing in Immunotherapeutics
Gene Therapy Pipeline Update: AGTC Presents Promising Data of its AAV Vectors for Ocular Gene Therapy
About Author
Arun_Gupta
Arun is an enthusiastic professional and has been associated with Roots Analysis since the very early years. He has led multifaceted roles over the years be it business research, consulting, competitive intelligence, IT & technology, sales and marketing. He currently drives strategic thinking and execution within the sales and marketing domain. With educational background in life sciences from Thapar University and digital marketing credentials from Indian School of Business, he has led a lot of critical initiatives at the organization. His background in life sciences has been one of the key reasons for quick understanding and implementation of customized marketing strategies. During his early years, he has led multiple consulting assignments for global clients ranging from competitive landscaping, deal structuring and preparing go-to-market strategy for his clients.